Study at a glance
What question did the studies ask?
Does vitamin D change immune ageing or persistent inflammation in older adults, and do those changes improve immune function? Studies measured cells, skin responses, vaccine antibodies and blood markers. Some experiments used cultured cells.
What did they find?
Selected cell-ageing markers decreased, and a local skin response improved. Other trials did not establish better measured immune function or vaccine responses. A VITAL analysis found a reduction in one inflammation marker at two years, but not four years. Several other markers did not improve.
What does this mean?
A laboratory change does not establish that the immune system becomes younger. A study needs to show that the change leads to meaningful improvement in function.
What are the limits?
Several studies were small or short. One clinical cohort appeared in two papers and is not two independent confirmations. Different populations and measurements limit comparison. These findings do not establish immune rejuvenation or an anti-ageing treatment.
Read the full article below ↓Vitamin D studies in older adults show that immune-cell measurements, local recall responses and circulating inflammatory markers can behave differently. Some findings suggest changes in selected biological processes, but the evidence does not establish reversal of immune ageing or a reliable improvement in whole-person immune competence. This review first examines age-related immune changes, then asks whether effects on chronic inflammation translate into better function. For the shorter account, read Vitamin D, Immune Ageing and the Gap Between Markers and Function: Study Summary.
Immune ageing is more than a blood test
Immunosenescence describes age-related changes in the immune system. It does not mean that every immune function declines together or that one laboratory marker can assign the immune system a biological age. The proportion of different cells, their responses to stimulation, local tissue conditions and clinical protection are separate questions. A useful interpretation must specify which of them a study actually measured.
The life-stage background in Vitamin D in Older Adults matters because older adults differ in health, activity, residence and starting vitamin D status. A small study in relatively healthy volunteers cannot automatically describe frail residents or people with major illness. Conversely, selecting people with low vitamin D does not guarantee that supplementation will improve an immune outcome. Both population and experimental comparison determine what can be inferred.
Vitamin D3 supplementation, circulating 25-hydroxyvitamin D and calcitriol exposure in cultured cells are also different scientific variables. Calcitriol is the active vitamin D hormone. A cell experiment using it can test a mechanism, but cannot establish the clinical effect of taking a vitamin D3 supplement. Vitamin D and Immune Modulation introduces immune regulation; evidence of regulation should not be rewritten as evidence of rejuvenation.
Cell composition does not establish younger immunity
Hwang and colleagues studied 34 healthy women older than 60. They compared circulating vitamin D with categories of CD8 T cells, including cells classified as naïve and effector cells. Higher vitamin D was associated with fewer naïve cells and more effector cells. This finding challenges a simple assumption that a higher blood concentration must accompany a conventionally younger-looking immune profile.
However, it does not establish that vitamin D accelerated immune ageing. The design was cross-sectional, with small groups and differences in racial composition. A restricted comparison was less convincing, and several functional, senescence and cytokine measurements did not differ significantly. Supplement exposure and other potential influences were incompletely resolved. The authors’ causal suggestion therefore goes beyond what the association alone can demonstrate.
The study is useful because it forces a distinction between a cell label and an outcome. Naïve cells have not yet acquired the same antigen experience as many differentiated cells, but counting them does not directly measure a person’s ability to avoid infection. Likewise, a larger experienced-cell fraction is not necessarily better memory. The underlying adaptive processes are introduced in Vitamin D and Adaptive Immunity; their clinical consequences still require appropriate functional measurements.
A local recall response in older skin
Chambers and colleagues followed 18 older adults with 25-hydroxyvitamin D below 75 nmol/L before and after 14 weeks of vitamin D3 at 6,400 international units (IU) daily. They examined responses to varicella-zoster antigen in the skin. The overall clinical response improved, but participants differed. A paired gene-expression analysis included 16 people, seven classified as improving by at least two points on the clinical score. The work connected local nonspecific inflammation with the ability to express an antigen-specific recall response.
This is closer to a functional immune question than simply counting cells. Nevertheless, it was an uncontrolled before-and-after study. Without a randomised placebo comparison, treatment effects cannot be separated securely from time, repeated testing or other influences. Responder subgroup findings also need to be distinguished from results in the whole group. Circulating inflammatory markers and whole-group antigen-related gene-expression comparisons did not show corresponding clear improvement.
The finding supports further investigation of the local tissue environment. It does not establish systemic immune rejuvenation, prevention of shingles or preservation of memory over years. The relationship to Vitamin D and Immune Memory is specifically recall after an earlier immune encounter. A changed skin response should retain that identity rather than become a broad claim of improved resistance to infection.
Fibroblast experiments explain a possibility, not a clinical result
Sayegh and colleagues examined calcitriol in cultured fibroblasts, cells that contribute to tissue structure and signalling. In the experimental senescence setting, calcitriol reduced selected inflammatory mediators and inhibited p38 signalling, a pathway involved in cellular responses to stress. This supplies a plausible link between the tissue environment and local immune responses. It does not show that vitamin D removes senescent cells or reverses all features of cellular ageing.
The human component reused the 18-person Chambers cohort. It is therefore not a second independent clinical replication. The laboratory component is informative in its own right, but cultured-cell exposure and oral supplementation cannot be substituted for one another. Comparisons with historical data from another intervention are also not a randomised head-to-head treatment comparison. The broader tissue question is covered in Vitamin D, Tissue Ageing and Senescence Markers: Full Evidence Review.
A trial changed some senescence-related markers
Rastgoo and colleagues randomised 88 older adults with low vitamin D into four groups for eight weeks. The study compared 1,000 and 5,000 IU vitamin D3 daily, with or without 600 mg N-acetylcysteine. Entry required 25-hydroxyvitamin D below 30 ng/mL (75 nmol/L). It measured senescence-related staining and gene expression in peripheral blood mononuclear cells, a mixed population of circulating immune cells. Higher-dose groups showed reductions in senescence-associated beta-galactosidase staining and selected p16 and inflammatory gene-expression measurements relative to the lower-dose control. The staining assesses enzyme activity associated with the studied cell state; it does not directly count cells removed or assign their age. The p21 gene-expression marker did not show a significant reduction.
These were active-treatment comparisons, not a vitamin-D-versus-no-vitamin-D trial. The additional N-acetylcysteine arms also require the combined and vitamin-D-only comparisons to be kept separate. The study’s correction changes a high-dose label from 50,000 to 5,000 IU; the corrected label must be used when interpreting the paper. Neither regimen should be converted into a personal treatment recommendation.
The trial did not establish a matching between-group benefit for circulating interleukin-6, C-reactive protein or the neutrophil-to-lymphocyte ratio. Interleukin-6 is an immune signalling protein; C-reactive protein is a blood marker used to assess inflammation. Multiple laboratory outcomes, small groups, short follow-up and mixed-cell assays limit interpretation. No improvement in infection resistance or daily functional competence was demonstrated by the selected marker changes.
This matters because the word senescence can sound like a complete diagnosis of cellular age. A staining result or gene-expression difference is evidence about that assay under those conditions. It does not establish removal of dysfunctional cells, restoration of the whole immune system, or a slower rate of ageing in the person. Those are larger propositions requiring additional evidence.
Functional comparisons include important null results
Dong and colleagues’ pilot trial randomised 24 adults aged 55 to 85, of whom 21 completed the study. It compared vitamin D3 at 1,000 IU daily with an education control over 12 weeks, without a placebo. Vitamin D concentrations increased, but the reported group-by-time comparisons for the principal immune measurements did not demonstrate benefit. These included selected inflammatory markers, phagocytosis and immune-cell proportions. Phagocytosis is the uptake of material by certain immune cells.
The trial was too small to establish equivalence or rule out every potentially useful effect. Yet its null comparisons cannot be presented as positive merely because vitamin D status rose. They also do not prove that a larger dose would have worked. The relevant result is a biochemical response without an established improvement in the measured immune functions under this design.
Gonçalves-Mendes and colleagues supply another functional comparison: 38 older adults with starting vitamin D below 30 ng/mL received vitamin D3 or placebo before influenza vaccination. The trial did not establish an overall improvement in antibody response, and selected strain-specific results favoured placebo. It also did not demonstrate the proposed cathelicidin benefit. Cathelicidin is an antimicrobial peptide. Small size and multiple outcomes restrict precision, but the low-status older population makes the null result directly relevant to ageing immunity.
Inflammageing: does less measured inflammation mean better competence?
Inflammageing refers to persistent inflammatory activity discussed in the context of ageing. It overlaps with the broader subject of Vitamin D and Chronic Inflammation, but it is not one disease, one cytokine or one laboratory threshold. To show that reducing a marker preserves immune competence, a study needs evidence for both the marker change and the functional consequence. Measuring only one side leaves the connection untested.
Waterhouse and colleagues analysed inflammatory biomarkers in a randomised pilot trial involving 644 adults aged 60 to 84, with post-treatment blood available for 613. Participants received 750 or 1,500 micrograms of vitamin D3 monthly (30,000 or 60,000 IU), or placebo, for a year. Most measured inflammatory outcomes did not show a clear treatment effect. An isolated high interleukin-6 comparison was not supported by the corresponding overall test or trend, so it should not be promoted into a robust inflammatory-harm conclusion either.
There were no baseline inflammatory measurements for analysing individual changes, several results were below assay detection limits, and multiple secondary comparisons were made. The study therefore supplies qualified evidence against a consistent anti-inflammatory effect under that regimen. It does not demonstrate that immune competence improved or deteriorated. This pilot is distinct from the later, much larger D-Health trial; similar names do not make them one population.
The four-year VITAL inflammation analysis reported by Dong and colleagues examined a clinic-based subgroup of the larger factorial trial, which assigned 2,000 IU vitamin D3 daily or placebo alongside a separate omega-3 comparison. The clinic subgroup comprised 1,054 participants. High-sensitivity C-reactive protein was 19% lower with vitamin D at two years, with nominal P=0.007 and multiplicity-adjusted P=0.028, but the result was not sustained at four years. Interleukin-6, interleukin-10 and tumour necrosis factor did not show corresponding treatment effects. Subgroup analyses did not establish a reliable differential benefit.
Samples numbered 1,051 at baseline, 977 at two years and 685 at four years; 29% of interleukin-6 measurements were outside the quantifiable range. These limitations affect precision and interpretation, without proving that missingness caused the result. The analysis did not demonstrate that the temporary C-reactive protein difference caused better immune function or fewer infections. Other VITAL reports share the parent trial and should not be counted as independent populations. The wider inflammation and biological-ageing interpretation is examined in Vitamin D, Long-Term Inflammation, Biological Ageing and Metabolic Risk: Full Evidence Review, while the present question is specifically whether such findings establish preserved immune competence.
These study regimens identify the interventions, not recommended personal doses. They cannot be assumed equivalent because their timing, comparators and participant selection differ.
Keeping the levels of evidence separate
| Finding | What it contributes | What it does not establish |
|---|---|---|
| Different T-cell proportions | A description of immune-cell composition | A causal change in immune age or protection |
| Senescence-related staining or gene expression | A change in selected cellular measurements | Whole-system rejuvenation |
| Local antigen recall | Functional information in the tested tissue | Prevention of infection throughout the body |
| A circulating inflammatory marker | Information about that marker and time point | A demonstrated pathway to stronger immunity |
| A vaccine antibody response | A defined response to vaccination | Durable protection against every infection |
The studies do not form a completed causal chain merely because each examines a neighbouring process. The cellular work can help explain hypotheses; the local recall study can identify a functional signal; the randomised trials can test particular intervention outcomes. Their different strengths are useful only when their limits remain visible. Combining them cannot supply a clinical outcome that none demonstrated.
Conclusion
Vitamin D signalling can influence selected cellular and inflammatory processes relevant to immune ageing. Human findings include a local recall signal and changes in some senescence-related measurements, alongside null functional and systemic inflammatory comparisons. The evidence does not establish that supplementation makes the immune system younger or reliably prevents the age-related decline in immune competence.
Future confirmation requires more than another favourable marker. It needs adequately designed comparisons that link relevant biological changes with meaningful immune function over time, while accounting for population differences and harms. Existing uncertainty is not proof that no effect is possible, but neither is it permission to assume benefit in people who were not studied. The current findings support a specific, qualified account of immune ageing rather than an anti-ageing treatment claim.
This review uses the assessed principal papers and verified claim-relevant material. Detailed supplementary subgroup and graph-only claims outside that inspected evidence are not included. The correction to Rastgoo’s paper is applied, and the reused Chambers population in Sayegh’s report is identified. These boundaries prevent incomplete access or repeated analysis of one cohort from appearing to strengthen the clinical evidence.
Sources
Related reading
Vitamin D3 replacement enhances antigen-specific immunity in older adults
We investigated the use of vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 years).
Original paper ↗Read more →Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Original paper ↗Read more →Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial
This randomized placebo-controlled double-blind trial investigated whether Vit-D supplementation in deficient elderly persons could improve influenza seroprotection and immune response.
Original paper ↗Read more →Vitamin D3 inhibits p38 MAPK and senescence‐associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing
Vitamin D3 replacement in older insufficient adults significantly improves their antigen‐specific varicella zoster virus (VZV) cutaneous immunity.
Original paper ↗Read more →Effects of micronutrient supplementation on immune function in older adults: a meta-analysis
This systematic review and meta-analysis of randomized controlled trials (RCTs) evaluate the impact of micronutrient supplementation on immune function in older adults.
Original paper ↗Read more →Epidemiology of 40 blood biomarkers of one-carbon metabolism, vitamin status, inflammation, and renal and endothelial function among cancer-free older adults
Imbalances of blood biomarkers are associated with disease, and biomarkers may also vary non-pathologically across population groups.
Original paper ↗Read more →Vitamin D, Long-Term Inflammation, Biological Ageing and Metabolic Risk: Full Evidence Review
Review VITAL, DO-HEALTH and TILDA findings on vitamin D, inflammatory markers, biological ageing and metabolic risk, with causal limits explained.
Read more →Frailty in Older Adults with Severe Aortic Stenosis: The Role of Systemic Inflammation and Calcium Homeostasis
This study aimed to analyze systemic inflammation and calcium homeostasis biomarkers and their associations with frailty in older adults with severe AoS.
Original paper ↗Read more →Investigation of the Relationship Between Glycemic Control and Inflammation-Nutrition Indices in Older Adults with Type 2 Diabetes
Objective: To investigate the relationship between glycemic control and inflammation: nutrition indices in older adults with type 2 diabetes mellitus and to evaluate their prognostic value for 30-day mortality.
Original paper ↗Read more →The serum vitamin D levels alleviate the influence of dietary inflammation on frailty: A cross-sectional analysis in the U.S. older adults
The current study aimed to explore the mediating association of vitamin D levels in the link between DI and frailty.
Original paper ↗Read more →Thirteen weeks of supplementation of vitamin D and leucine-enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study
A chronic low-grade inflammatory profile (CLIP) is associated with sarcopenia in older adults.
Original paper ↗Read more →Vitamin D status & associations with inflammation in older adults
We aimed to investigate the association of C-reactive protein (CRP) with vitamin D status in a representative sample of the older Irish population.
Original paper ↗Read more →Multiple simulated spaceflight stressors impact cardiac fibrosis, calcium dynamics, immune function, cytokines and gene variants in rat, Rattus norvegicus
Exposure to 1.5 Gy of simGCRsim with or without HLU increased cardiac perivascular collagen content, the primary endpoint, compared to sham-irradiated no HLU rats after 270 days.
Original paper ↗Read more →The Role of Vitamin D3 in Periodontal Health: Implications for Bone Metabolism, Immune Modulation and Inflammation Control
Vitamin D3 is a fat-soluble steroid essential for bone metabolism, immune modulation, and inflammation control, all critical for periodontal health.
Original paper ↗Read more →Vitamin D, Immune Ageing and the Gap Between Markers and Function: Study Summary
What studies in older adults found about vitamin D, immune cells and inflammation, explained simply with the main limits and null results.
Read more →Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial Comparing Lacticaseibacillus paracasei PS23 Probiotic with Heat-Treated Supplementation
This study recruited 119 participants, aged 65 to 85 years, and randomly assigned them to receive a placebo (0 × 1010 CFU/day), L-PS23 (live PS23, 2 × 1010 CFU/day), or HT-PS23 (heat-treated PS23, 2 × 1010 cells/day) for a duration of 12 weeks.
Original paper ↗Read more →Obesity, Physical Fitness and Inflammation in the Elderly
In a sub-sample, blood samples were collected and objective markers of inflammation were provided: high-sensitivity C-reactive protein (hs-CRP) and Vitamin D (25(OH) D).
Original paper ↗Read more →Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation: A Randomized, Placebo-Controlled Trial
We investigated if the novel combination of a multi-strain probiotic (containing B.
Original paper ↗Read more →Preoperative vitamin D insufficiency increases the risk of delayed neurocognitive recovery via acute systemic inflammation in elderly women undergoing gynecological surgery
Delayed neurocognitive recovery (DNR) is common among elderly women following gynecological surgery.
Original paper ↗Read more →The relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted to hospital with COVID-19
The aim of the present study was to examine the relationship between micronutrient status, frailty, systemic inflammation, and clinical outcomes in patients admitted with COVID-19.
Original paper ↗Read more →Vitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Study Summary
Summary of a vitamin D trial in deficient adults: higher blood levels, no clear inflammatory improvement, and key limits of the 16-week findings.
Read more →Original sources
Vitamin D3 replacement enhances antigen-specific immunity in older adults
We investigated the use of vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 years).
Publication details
Chambers et al. (2021). Vitamin D3 replacement enhances antigen-specific immunity in older adults. Immunotherapy Advances. 1(1):ltaa008. DOI: 10.1093/immadv/ltaa008.
Vitamin D3 inhibits p38 MAPK and senescence‐associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing
Vitamin D3 replacement in older insufficient adults significantly improves their antigen‐specific varicella zoster virus (VZV) cutaneous immunity.
Publication details
Sayegh et al. (2024). Vitamin D3 inhibits p38 MAPK and senescence‐associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Aging Cell. 23(4):e14093. DOI: 10.1111/acel.14093.
Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
Published in Frontiers in Immunology. 16:1570441. DOI: 10.3389/fimmu (2025).
Publication details
Rastgoo et al. (2025). Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Frontiers in Immunology. 16:1570441. DOI: 10.3389/fimmu.2025.1570441.
Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial
Published in Frontiers in Immunology. 16:1627178. Correction. DOI: 10.3389/fimmu (2025).
Publication details
Rastgoo et al. (2025). Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Frontiers in Immunology. 16:1627178. Correction. DOI: 10.3389/fimmu.2025.1627178.
Influence of vitamin D supplementation on immune function of healthy aging people: A pilot randomized controlled trial
Published in Frontiers in Nutrition. 9:1005786. DOI: 10.3389/fnut (2022).
Publication details
Dong et al. (2022). Influence of vitamin D supplementation on immune function of healthy aging people: A pilot randomized controlled trial. Frontiers in Nutrition. 9:1005786. DOI: 10.3389/fnut.2022.1005786.
Increased vitamin D is associated with decline of naïve, but accumulation of effector, CD8 T cells during early aging
Published in Advances in aging research. 2(2):72-80. DOI: 10.4236/aar (2013).
Publication details
Hwang et al. (2013). Increased vitamin D is associated with decline of naïve, but accumulation of effector, CD8 T cells during early aging. Advances in aging research. 2(2):72-80. DOI: 10.4236/aar.2013.22010.
Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial
This randomized placebo-controlled double-blind trial investigated whether Vit-D supplementation in deficient elderly persons could improve influenza seroprotection and immune response.
Publication details
Gonçalves-Mendes et al. (2019). Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial. Frontiers in Immunology. 10:65. DOI: 10.3389/fimmu.2019.00065.
Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial
Waterhouse et al. (2015).
Publication details
Waterhouse et al. (2015). Effect of vitamin D supplementation on selected inflammatory biomarkers in older adults: a secondary analysis of data from a randomised, placebo-controlled trial. The British journal of nutrition. 114(5):693-699. DOI: 10.1017/S0007114515002366.
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Publication details
Dong et al. (2022). Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 14(24):5307. DOI: 10.3390/nu14245307.